Major Drugs - South Farmingdale, NY, US
DepYmed is currently developing potent inhibitors of the enzyme PTP1B as therapeutics for cancer and rare diseases. In addition, DepYmed has developed a portfolio of novel small molecules with copper chelating properties that can be applied as potential therapeutic agents for multiple diseases including Wilson Disease and cancer.
reCAPTCHA
Apache
Weebly
Google Font API
Google Analytics
YouTube